Skip to main content

Applied Therapeutics, Inc. (APLT)

NASDAQ: APLT · IEX Real-Time Price · USD
14.26 -0.10 (-0.70%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap373.30M
Revenue (ttm)n/a
Net Income (ttm)-103.54M
Shares Out26.08M
EPS (ttm)-4.35
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume155,777
Open14.44
Previous Close14.36
Day's Range14.04 - 14.76
52-Week Range13.58 - 29.80
Beta1.13
AnalystsStrong Buy
Price Target42.83 (+200.4%)
Est. Earnings DateNov 11, 2021

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III ...

IndustryBiotechnology
IPO DateMay 14, 2019
Employees26
Stock ExchangeNASDAQ
Ticker SymbolAPLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for APLT stock is "Strong Buy." The 12-month stock price forecast is 42.83, which is an increase of 200.35% from the latest price.

Price Target
$42.83
(200.35% upside)
Analyst Consensus: Strong Buy

News

Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate

Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of the 47 children enrolled in the study. Related Cont...

1 week ago - Benzinga

Applied Therapeutics Reports Second Quarter 2021 Financial Results

NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing

1 month ago - GlobeNewsWire

Applied Therapeutics Added to Russell Microcap® Index

NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

2 months ago - GlobeNewsWire

Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientif...

~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart's ability to function   People with diabetes or pre-diabetes who have D...

2 months ago - GlobeNewsWire

Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions ...

NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

2 months ago - GlobeNewsWire

Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder

The FDA has granted Fast Track designation to Applied Therapeutics Inc's (NASDAQ: APLT) AT-007 to treat Galactosemia, a rare metabolic disease. AT-007 is the Company's central nervous system-penetrant A...

3 months ago - Benzinga

Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

3 months ago - GlobeNewsWire

Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

3 months ago - GlobeNewsWire

Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference

NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecula...

4 months ago - GlobeNewsWire

Applied Therapeutics Reports First Quarter 2021 Financial Results

Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency

4 months ago - GlobeNewsWire

Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results

AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA

6 months ago - GlobeNewsWire

Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

6 months ago - GlobeNewsWire

Applied Therapeutics, Inc. Announces Closing of Public Offering

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

6 months ago - GlobeNewsWire

Applied Therapeutics Raises $69M Via Equity

Applied Therapeutics Inc (NASDAQ: APLT) prices its underwritten public offering of 3 million at $23 per share, raising $69 million in gross proceeds, at a marginal premium of 2%. Underwriters have an op...

7 months ago - Benzinga

Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

7 months ago - GlobeNewsWire

Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares of Common Stock

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

7 months ago - GlobeNewsWire

Applied Therapeutics Announces Restart of Pediatric Galactosemia Study

FDA Clinical Hold Lifted

7 months ago - GlobeNewsWire

Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

9 months ago - GlobeNewsWire

Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

9 months ago - GlobeNewsWire

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)

10 months ago - GlobeNewsWire

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopat...

Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) Treatment with AT-001 normalizes cardiac energetics and improves card...

10 months ago - GlobeNewsWire

Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Gen...

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

10 months ago - GlobeNewsWire

Applied Therapeutics Inc. (APLT) Stock Sinks As Market Gains: What You Should Know

Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.

11 months ago - Zacks Investment Research

Could Applied Therapeutics Stock Rise 300%?

Applied Therapeutics Inc. (NASDAQ: APLT) shares pushed higher on Thursday after a new analyst report came out supposing massive upside for this biotech.

11 months ago - 24/7 Wall Street

Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know

Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.

11 months ago - Zacks Investment Research